Skip to main content
Top
Published in: Thrombosis Journal 1/2013

Open Access 01-12-2013 | Review

Main considerable factors for correct laboratory test interpretation under DOA treatment

Authors: Helen Mani, Edelgard Lindhoff-Last

Published in: Thrombosis Journal | Issue 1/2013

Login to get access

Abstract

Summary

To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will be released each year over the next few years. Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.
In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are described.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ageno W, Gallus AS, Wittkowsky A, et al.: Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):e44S-88S.PubMedCentralPubMed Ageno W, Gallus AS, Wittkowsky A, et al.: Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):e44S-88S.PubMedCentralPubMed
2.
go back to reference Samama MM, Guinet C, Le Flem L: Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012, 130(Suppl 1):S88-89.CrossRefPubMed Samama MM, Guinet C, Le Flem L: Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012, 130(Suppl 1):S88-89.CrossRefPubMed
3.
go back to reference Lindhoff-Last E, Samama MM, Ortel TL, et al.: Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32(6):673-69. 10.1097/FTD.0b013e3181f2f264CrossRefPubMed Lindhoff-Last E, Samama MM, Ortel TL, et al.: Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32(6):673-69. 10.1097/FTD.0b013e3181f2f264CrossRefPubMed
4.
go back to reference Wienen W, Stassen JM, Priepke H, et al.: In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007, 98: 155-162.PubMed Wienen W, Stassen JM, Priepke H, et al.: In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007, 98: 155-162.PubMed
5.
go back to reference Samama MM, Martinoli JL, LeFlem L, et al.: Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103(4):815-825. 10.1160/TH09-03-0176CrossRefPubMed Samama MM, Martinoli JL, LeFlem L, et al.: Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103(4):815-825. 10.1160/TH09-03-0176CrossRefPubMed
6.
go back to reference Lindahl TL Baghaei F, Blixter IF, et al.: Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011, 105(2):371-378.CrossRefPubMed Lindahl TL Baghaei F, Blixter IF, et al.: Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011, 105(2):371-378.CrossRefPubMed
7.
go back to reference Mani H, Hesse C, Stratmann G, Lindhoff-Last E: Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011, 106(1):156-164. 10.1160/TH10-10-0667CrossRefPubMed Mani H, Hesse C, Stratmann G, Lindhoff-Last E: Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011, 106(1):156-164. 10.1160/TH10-10-0667CrossRefPubMed
8.
go back to reference Douxfils J, Mullier F, Robert S, et al.: Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012, 107(5):985-997. 10.1160/TH11-11-0804CrossRefPubMed Douxfils J, Mullier F, Robert S, et al.: Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012, 107(5):985-997. 10.1160/TH11-11-0804CrossRefPubMed
9.
go back to reference van Ryn J, Stangier J, Haertter S, et al.: Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103(6):1116-1127. 10.1160/TH09-11-0758CrossRefPubMed van Ryn J, Stangier J, Haertter S, et al.: Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103(6):1116-1127. 10.1160/TH09-11-0758CrossRefPubMed
10.
go back to reference Mani H, Hesse C, Stratmann G, Lindhoff-Last E: Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013, 109(1):127-136.CrossRefPubMed Mani H, Hesse C, Stratmann G, Lindhoff-Last E: Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013, 109(1):127-136.CrossRefPubMed
11.
go back to reference Douxfils J, Mullier F, Loosen C, et al.: Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012, 130(6):956-966. 10.1016/j.thromres.2012.09.004CrossRefPubMed Douxfils J, Mullier F, Loosen C, et al.: Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012, 130(6):956-966. 10.1016/j.thromres.2012.09.004CrossRefPubMed
12.
go back to reference Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL: Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9(1):133-139. 10.1111/j.1538-7836.2010.04098.xCrossRefPubMed Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL: Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9(1):133-139. 10.1111/j.1538-7836.2010.04098.xCrossRefPubMed
13.
go back to reference Freyburger G, Macouillard G, Labrouche S, Sztark F: Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127(5):457-465. 10.1016/j.thromres.2011.01.001CrossRefPubMed Freyburger G, Macouillard G, Labrouche S, Sztark F: Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127(5):457-465. 10.1016/j.thromres.2011.01.001CrossRefPubMed
14.
go back to reference Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F: Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013, 110(2):283-294. 10.1160/TH12-12-0898CrossRefPubMed Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F: Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013, 110(2):283-294. 10.1160/TH12-12-0898CrossRefPubMed
15.
go back to reference Baglin T, Keeling D, Kitchen S: British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012, 159(4):427-429. 10.1111/bjh.12052CrossRefPubMed Baglin T, Keeling D, Kitchen S: British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012, 159(4):427-429. 10.1111/bjh.12052CrossRefPubMed
16.
go back to reference Herth N, Mani H, Wenger F, et al.: Dabigatran influences ex-vivo global coagulation assays in dependence of time of drug intake. Haemostaseologie 2011, A89(1):P17.5. Herth N, Mani H, Wenger F, et al.: Dabigatran influences ex-vivo global coagulation assays in dependence of time of drug intake. Haemostaseologie 2011, A89(1):P17.5.
Metadata
Title
Main considerable factors for correct laboratory test interpretation under DOA treatment
Authors
Helen Mani
Edelgard Lindhoff-Last
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2013
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-11-22

Other articles of this Issue 1/2013

Thrombosis Journal 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.